Kayentis (global provider of eCOA and DCT solutions) and RWS (language service provider (LSP) and linguistic validation experts) were selected to create and implement the electronic versions of the COAs (eCOAs) on a high priority study with a new client, pioneer in biotechnology.
The study is a Global Small Cell Lung Cancer Phase II Study, spanning 26 languages and 7 instruments, with 100 participating sites.

The long-standing partnership between Kayentis and RWS enabled a successful study start-up so that the final study materials were completed and delivered earlier than quoted timelines.
The collaborative efforts established between both partners helped mitigate any potential delays arising from external review requirements and changing priorities to ensure a successful study.